Skip to main content
SpringerLink
Log in

Immunotherapy for rhinitis

  • Published:
Current Allergy and Asthma Reports Aims and scope Submit manuscript

Abstract

Allergen-specific immunotherapy in the treatment of allergic rhinitis has a well-documented clinical efficacy that indicates a statistically significant and clinically relevant reduction in symptom scores and the need for pharmacotherapy. The clinical efficacy of recently published studies is equivalent to or superior to the effect of standard antiallergic drugs. Additional advantages are related to a downregulation of the allergic phenotype with the additional induction of a Th1 cytokine profile. The immunoregulatory capacity and the global downregulation of the allergic inflammation in mucous membranes might be important factors in the capacity to ensure long-term clinical efficacy (after termination of treatment) and the preventive capacity of immunotherapy in reducing the progression of rhinitis to asthma as well as deflowering the development of new sensitizations. Subcutaneous immunotherapy is optimal in severe allergic rhinitis with signs of bronchial hyperreactivity; however, sublingual immunotherapy might be an option for patients with milder disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Sly RM: Changing prevalence of allergic rhinitis and asthma. Ann Allergy Asthma Immunol 1999, 82:233–248.

    PubMed  CAS  Google Scholar 

  2. Bousquet J, Van Cauvenberge P, Khaltaev N: Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001, 108:147–334. A comprehensive review of epidemiology, pathophysiology, co-morbidity, diagnosis, and management of allergic rhinitis including the important link between rhinitis and asthma. The guidelines are evidence-based and include almost 2800 references.

    Article  Google Scholar 

  3. Linna O, Kokkonen J, Lukin M: A 10-year prognosis for childhood allergic rhinitis. Acta Paedriatr 1992, 81:100–102.

    CAS  Google Scholar 

  4. Settipane RJ, Hagy GW, Settipane GA: Long-term risk factors for developing asthma and allergic rhinitis: a 23-year followup study of college students. Allergy Proc 1994, 15:21–25.

    Article  PubMed  CAS  Google Scholar 

  5. Madonini E, Briatico Vangosa G, Pappacoda A, et al.: Seasonal increase of bronchial reactivity in allergic rhinitis. J Allergy Clin Immunol 1987, 79:358–363.

    Article  PubMed  CAS  Google Scholar 

  6. Braman SS, Barrows AA, DeCotiis BA, et al.: Airway hyperresponsiveness in allergic rhinitis: a risk factor for asthma. Chest 1987, 91:671–674.

    PubMed  CAS  Google Scholar 

  7. Malling H-J: Immunotherapy as an effective tool in allergy treatment. Allergy 1998, 53:461–472.

    Article  PubMed  CAS  Google Scholar 

  8. Bousquet J, Lockey RF, Malling H-J (eds): WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998, 53(Suppl 44):1–42.

    Google Scholar 

  9. Malling H-J, Abreu-Nogueira J, Alvarez-Cuesta E, et al.: Local immunotherapy: position paper from EAACI & ESPACI. Allergy 1998, 53:933–944.

    Article  PubMed  CAS  Google Scholar 

  10. Malling H-J: Is sublingual immunotherapy clinically effective? Curr Opin Allergy Clin Immunol 2002, 2:523–531. A critical review of the clinical efficacy of sublingual immunotherapy based on all placebo-controlled, double-blind studies.

    Article  PubMed  Google Scholar 

  11. Ross RN, Nelson HS, Finegold I: Effectiveness of specific immunotherapy in the treatment of allergic rhinitis: an analysis of randomized, prospective, single- or double-blind, placebo-controlled studies. Clin Ther 2000, 22:342–350.

    Article  PubMed  CAS  Google Scholar 

  12. Walker SM, Pajno GB, Torres Lima M, et al.: Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomised controlled trial. J Allergy Clin Immunol 2001, 107:87–93. A model study of immunotherapy showing the clinically relevant efficacy of rhinitis symptoms, improvement in quality of life, and a reduction in seasonal asthma and bronchial hyperresponsiveness.

    Article  PubMed  CAS  Google Scholar 

  13. Leynadier F, Banoun L, Dollois B, et al.: Immunotherapy with calcium phosphate-adsorbed five-grass-pollen extract in seasonal rhinoconjunctivitis: a double-blind, placebo-controlled study. Clin Exp Allergy 2001, 31:988–996.

    Article  PubMed  CAS  Google Scholar 

  14. Rak S, Heinrich C, Jacobsen L, et al.: A double-blind, comparative study of the effects of short preseason specific immunotherapy and topical steroids in patients with allergic rhinoconjunctivitis and asthma. J Allergy Clin Immunol 2001, 108:921–928. Comparison of the clinical efficacy of immunotherapy with intranasal steroids including the preventive capacity of immunotherapy on bronchial hyperresponsiveness and seasonal downregulation of eosinophils.

    Article  PubMed  CAS  Google Scholar 

  15. Bødtger U, Poulsen LK, Jacobi H, Malling H-J: The safety and efficacy of subcutaneous birch pollen immunotherapy: a one-year, randomized, double-blind, placebo-controlled study. Allergy 2002, 57:297–305.

    Article  PubMed  Google Scholar 

  16. Guez S, Vatrinet C, Fadel R, Andre C: House-dust-mite sublingualswallow immunotherapy (SLIT) in perennial rhinitis: a doubleblind, placebo-controlled study. Allergy 2000, 55:369–375.

    Article  PubMed  CAS  Google Scholar 

  17. Pajno GB, Morabito L, Barberio G, Parmiani S: Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a doubleblind, placebo-controlled study. Allergy 2000, 55:842–849.

    Article  PubMed  CAS  Google Scholar 

  18. Cafferelli C, Sensi LG, Marcucci F, Cavagni G: Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial. Allergy 2000, 55:1142–1147.

    Article  Google Scholar 

  19. Bahceciler NN, Isik U, Barlan IB, Basaran MM: Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr Pulmonol 2001, 32:49–55.

    Article  PubMed  CAS  Google Scholar 

  20. Voltolini S, Modena P, Minale P, et al.: Sublingual immunotherapy in tree pollen allergy: double-blind, placebo-controlled study with a biologically standardised extract of three pollens (alder, birch, and hazel) administered by a rush schedule. Allergol Immunopathol (Madr) 2001, 29:103–110.

    CAS  Google Scholar 

  21. Ariano R, Spadolini I, Panzani RC: Efficacy of sublingual specific immunotherapy in Cupressaceae allergy using an extract of Cupressus arizonica: a double blind study. Allergol Immunopathol 2001, 29:238–244.

    CAS  Google Scholar 

  22. Torres Lima M, Wilson D, Pitkin L, et al.: Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. Clin Exp Allergy 2002, 32:507–514.

    Article  Google Scholar 

  23. Quirino T, Iemoli E, Siciliani E, et al.: Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study. Clin Exp Allergy 1996, 26:1253–1261.

    Article  PubMed  CAS  Google Scholar 

  24. Mungan D, Misirligil Z, Gurbuz L: Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mitesensitive patients with rhinitis and asthma: a placebo controlled study. Ann Allergy Asthma Immunol 1999, 82:485–490.

    Article  PubMed  CAS  Google Scholar 

  25. Khinchi MS, Poulsen LK, Carat F, et al.: Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, doubleblind, double-dummy study.

  26. Durham SR, Walker SM, Varga EM, et al.: Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999, 341:468–475.

    Article  PubMed  CAS  Google Scholar 

  27. Varney VA, Gaga M, Frew AJ, et al.: Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. Br Med J 1991, 302:265–269.

    Article  CAS  Google Scholar 

  28. Eng PA, Reinhold M, Gnehm HPE: Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy 2002, 57:306–312.

    Article  PubMed  CAS  Google Scholar 

  29. Purello-D’Ambrosio F, Gangemi S, Merendino RA, et al.: Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not: a retrospective study. Clin Exp Allergy 2001, 31:1295–1302.

    Article  PubMed  CAS  Google Scholar 

  30. Pajno GB, Barberio G, de Luca Fr, et al.: Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy: a six-year follow-up study. Clin Exp Allergy 2001, 31:1392–1397.

    Article  PubMed  CAS  Google Scholar 

  31. Möller C, Dreborg S, Ferdousi HA, et al.: Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT study). J Allergy Clin Immunol 2002, 109:251–256. A multi-center study of the important preventive capacity of immunotherapy on the development of asthma in patients with seasonal rhinitis and improvement in bronchial hyperresponsiveness.

    Article  PubMed  Google Scholar 

  32. Durham SR, Ying S, Varney VA: Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-_. J Allergy Clin Immunol 1996, 97:1356–1365.

    Article  PubMed  CAS  Google Scholar 

  33. Durham SR, Varney VA, Gaga M, et al.: Grass pollen immunotherapy decreases the number of mast cells in the skin. Clin Exp Allergy 1999, 29:1490–1496.

    Article  PubMed  CAS  Google Scholar 

  34. Wachholz PA, Nouri-Aria KT, Wilson DR, et al.: Grass pollen immunotherapy for hay fever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios. Immunology 2002, 105:56–62.

    Article  PubMed  CAS  Google Scholar 

  35. Wilson DR, Irani A-MA, Walker SM, et al.: Grass pollen immunotherapy inhibits seasonal increase in basophils and eosinophils in the nasal epithelium. Clin Exp Allergy 2001, 31:1705–1713.

    Article  PubMed  CAS  Google Scholar 

  36. Wilson DR, Nouri-Aria KT, Walker SM, et al.: Grass pollen immunotherapy: symptomatic improvement correlates with reduction in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season. J Allergy Clin Immunol 2001, 107:971–976.

    Article  PubMed  CAS  Google Scholar 

  37. Erel F, Karaayvaz M, Caliskaner AZ, et al.: Effects of allergen immunotherapy on the nasal mucosa in patients with allergic rhinitis. J Investig Allergol Clin Immunol 2000, 10:14–19.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Allergy Clinic 4222, National University Hospital, Blegdamsvej 9, 2100, Copenhagen, Denmark

    Hans-Jørgen Malling MD

Authors
  1. Hans-Jørgen Malling MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Malling, HJ. Immunotherapy for rhinitis. Curr Allergy Asthma Rep 3, 204–209 (2003). https://doi.org/10.1007/s11882-003-0040-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11882-003-0040-7

Keywords

Search

Navigation